Special Translational Research Acceleration Projects (STRAPs)
In the summer of 2010, CCCT released a Notice entitled "Administrative Supplements to Advance Special Translational Research Acceleration Projects (STRAP) on Immune Response Modifiers (IRM) Currently Funded by the National Cancer Institute (NCI)"
The goal of this particular STRAP opportunity was to accelerate translational research focused on the Immune Response Modifier (IRM) pathway by way of supplemental funding to an investigator's existing NCI-funded grant.
After a rigorous evaluation, two submissions were selected for funding:
STRAP Awards Funded in 2010
|Principal Investigator:||Andrew A. Raubitschek||Beckman Research Institute of City of Hope|
|Supplement to Grant:||P01 CA043904||R01 CA138738|
|Grant Title:||Antibody Targeted Radiation and Immunotherapy for the Treatment of Solid Tumors||Adoptive Immunotherapy of Cancer with IL-12 Secreting Tumor-Targeted T cells|
|Applicant Organization:||Beckman Research Institute of City of Hope||Sloan-Kettering Institute for Cancer Research|
Funding Opportunity Guidelines and FAQs
- Guidelines for the Notice (NOT-CA-10-025): IRM STRAP (Receipt date: July 15, 2010)
- Frequently Asked Questions (FAQs) about the IRM STRAP funding opportunity (07/01/2010)
The funding opportunity (NOT-CA-10-025 and Notice Guidelines) for the Immune Response Modifier (IRM) Special Translational Research Acceleration Project (STRAP) is the implementation of a key recommendation of the NCI sponsored Translational Research Working Group (TRWG).
The TRWG recommended identifying a few projects that are "ripe" for translation, and have NCI provide the financial resources and the project coordination required to expedite moving those projects to the point of early stage clinical trials.
The TRWG was charged with evaluating the status of the NCIs investments in translational research and envisioning the future in an inclusive, representative, and transparent manner. In 2007, the NCI accepted the 15 TRWG recommendations to accelerate translational cancer research as outlined in the report entitled "Transforming Translation: Harnessing Discovery for Patient and Public Benefit."
The IRM pathway is one of six developmental Pathways derived from the TRWG deliberations. The Pathways are process diagrams that outline the steps required to advance a basic science discovery through early phase clinical trials (Clinical Cancer Research 14: 5663-5713, 2008). The Pathways are expected to serve as useful tools for the research community, allowing individual investigators/programs focused on one aspect of a translational research question to consider their work within a broader developmental context and prompting them to develop the collaborations necessary to move their research forward.
Extensive extramural scientific input was solicited to help define priorities within cancer immunology for accelerated research attention. Within cancer immunoprevention and immunotherapy the following were identified as important opportunity areas:
- Adoptive cell therapy;
- Antibody or "T-body" therapy;
- Cancer vaccine targeting a viral antigen; and
- Vaccine targeting a cellular antigen (self or tumor).
In addition, specific immune components were prioritized including Immune Modifying Agents (IMAs) and Target Antigens.